FASEB J. Avanti Polar Lipids
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Published as doi: 10.1096/fj.06-6228fje.
This Article
Right arrow Summary
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
fj.06-6228fjev1
20/13/2384    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Liu, H.
Right arrow Articles by Visner, G. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Liu, H.
Right arrow Articles by Visner, G. A.
(The FASEB Journal. 2006;20:2384-2386.)
© 2006 FASEB

Sleeping Beauty-based gene therapy with indoleamine 2,3-dioxygenase inhibits lung allograft fibrosis

Hanzhong Liu*, Li Liu{dagger}, Bradley S. Fletcher{dagger},{ddagger} and Gary A. Visner*,1

* Department of Pediatrics, Children’s Hospital of Philadelphia, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA;

{dagger} Department of Pharmacology and Therapeutics, University of Florida, Gainesville, Florida, USA; and

{ddagger} Medical Research Service, Department of Veteran Affairs Medical Canter, Gainesville, Florida, USA

1Correspondence: Division of Pulmonary Medicine, Children’s Hospital of Philadelphia, 34th and Civic Center Blvd., Abramson Research Bldg., 916D, Philadelphia, PA 19104, USA. E-mail: visner{at}email.chop.edu

ABSTRACT

Sleeping Beauty (SB) transposon is a natural nonviral gene transfer system that can mediate long-term transgene expression. Its potential utility in treating organ transplantation-associated long-term complications has not yet been explored. In the present study we generated an improved SB transposon encoding the human gene indoleamine-2,3-dioxygenase (hIDO), an enzyme that possesses both T cell-suppressive and antioxidant properties and selectively delivered the SB transposon in combination with a hyperactive transposase plasmid to donor lung using the cationic polymer polyethylenimine (PEI) as transfection reagent. This nonviral gene therapeutic approach led to persistent and uniform transgene expression in the rat lung tissue without noticeable toxicity and inflammation. Importantly, IDO activity produced by hIDO transgene showed a remarkable therapeutic response, as evident by near normal pulmonary function (peak airway pressure and oxygenation), histological appearance, and reduced collagen content in lung allografts. In addition, we established a hIDO-overexpressing type II cell line using the SB-based gene transfer system and found that hIDO-overexpressing lung cells effectively inhibited transforming growth factor-ß-stimulated fibroblast proliferation in vitro. In summary, the SB-based gene therapy with hIDO represents a new strategy for treating lung transplantation-associated chronic complications, e.g., obliterative bronchiolitis.—Liu, H., Liu, L., Fletcher, B. S., Visner, G. A. Sleeping Beauty-based gene therapy with indoleamine 2,3-dioxygenase inhibits lung allograft fibrosis.




This article has been cited by other articles:


Home page
Hum Reprod UpdateHome page
L. R. Guerin, J. R. Prins, and S. A. Robertson
Regulatory T-cells and immune tolerance in pregnancy: a new target for infertility treatment?
Hum. Reprod. Update, March 11, 2009; (2009) dmp004v1.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
L. K. Jasperson, C. Bucher, A. Panoskaltsis-Mortari, P. A. Taylor, A. L. Mellor, D. H. Munn, and B. R. Blazar
Indoleamine 2,3-dioxygenase is a critical regulator of acute graft-versus-host disease lethality
Blood, March 15, 2008; 111(6): 3257 - 3265.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
A. C. Burman, T. Banovic, R. D. Kuns, A. D. Clouston, A. C. Stanley, E. S. Morris, V. Rowe, H. Bofinger, R. Skoczylas, N. Raffelt, et al.
IFN{gamma} differentially controls the development of idiopathic pneumonia syndrome and GVHD of the gastrointestinal tract
Blood, August 1, 2007; 110(3): 1064 - 1072.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2006 by The Federation of American Societies for Experimental Biology.